Partial hepatectomy accelerates colorectal metastasis by priming an inflammatory premetastatic niche in the liver.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 19 02 2024
accepted: 27 05 2024
medline: 26 6 2024
pubmed: 26 6 2024
entrez: 26 6 2024
Statut: epublish

Résumé

Resection of colorectal liver metastasis is the standard of care for patients with Stage IV CRC. Despite undoubtedly improving the overall survival of patients, pHx for colorectal liver metastasis frequently leads to disease recurrence. The contribution of this procedure to metastatic colorectal cancer at a molecular level is poorly understood. We designed a mouse model of orthograde metastatic colorectal cancer (CRC) to investigate the effect of partial hepatectomy (pHx) on tumor progression. CRC organoids were implanted into the cecal walls of wild type mice, and animals were screened for liver metastasis. At the time of metastasis, 1/3 partial hepatectomy was performed and the tumor burden was assessed longitudinally using MRI. After euthanasia, different tissues were analyzed for immunological and transcriptional changes using FACS, qPCR, RNA sequencing, and immunohistochemistry. Mice that underwent pHx presented significant liver hypertrophy and an increased overall metastatic load compared with SHAM operated mice in MRI. Elevation in the metastatic volume was defined by an increase in Regenerative pathways following pHx accelerate colorectal metastasis to the liver by priming a premetastatic niche.

Sections du résumé

Background UNASSIGNED
Resection of colorectal liver metastasis is the standard of care for patients with Stage IV CRC. Despite undoubtedly improving the overall survival of patients, pHx for colorectal liver metastasis frequently leads to disease recurrence. The contribution of this procedure to metastatic colorectal cancer at a molecular level is poorly understood. We designed a mouse model of orthograde metastatic colorectal cancer (CRC) to investigate the effect of partial hepatectomy (pHx) on tumor progression.
Methods UNASSIGNED
CRC organoids were implanted into the cecal walls of wild type mice, and animals were screened for liver metastasis. At the time of metastasis, 1/3 partial hepatectomy was performed and the tumor burden was assessed longitudinally using MRI. After euthanasia, different tissues were analyzed for immunological and transcriptional changes using FACS, qPCR, RNA sequencing, and immunohistochemistry.
Results UNASSIGNED
Mice that underwent pHx presented significant liver hypertrophy and an increased overall metastatic load compared with SHAM operated mice in MRI. Elevation in the metastatic volume was defined by an increase in
Conclusions UNASSIGNED
Regenerative pathways following pHx accelerate colorectal metastasis to the liver by priming a premetastatic niche.

Identifiants

pubmed: 38919609
doi: 10.3389/fimmu.2024.1388272
pmc: PMC11196966
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1388272

Informations de copyright

Copyright © 2024 Luenstedt, Hoping, Feuerstein, Mauerer, Berlin, Rapp, Marx, Reichardt, von Elverfeldt, Ruess, Plundrich, Laessle, Jud, Neeff, Holzner, Fichtner-Feigl and Kesselring.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Jost Luenstedt (J)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Fabian Hoping (F)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Reinhild Feuerstein (R)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Bernhard Mauerer (B)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Christopher Berlin (C)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Julian Rapp (J)

Eye Center, University Medical Center Freiburg, Freiburg, Germany.
Department of Medicine I, University Medical Center Freiburg, Freiburg, Germany.

Lisa Marx (L)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Wilfried Reichardt (W)

Division of Medical Physics, Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Dominik von Elverfeldt (D)

Division of Medical Physics, Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Dietrich Alexander Ruess (DA)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Dorothea Plundrich (D)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Claudia Laessle (C)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Andreas Jud (A)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Hannes Philipp Neeff (HP)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Philipp Anton Holzner (PA)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Stefan Fichtner-Feigl (S)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Rebecca Kesselring (R)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH